IL-13
Interleukin-13 (IL-13) is a type 2 cytokine primarily produced by Th2 cells, regulating immune responses through modulation of macrophage and epithelial cell activity[1]. Mechanistically, IL-13 signals via the IL-4 receptor alpha (IL-4Rα)/IL-13Rα1 heterodimer, activating the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway, particularly STAT6, to induce gene expression associated with allergic inflammation and tissue remodeling[2][3]. In disease models such as experimental autoimmune encephalomyelitis (EAE), IL-13 exerts anti-inflammatory effects by suppressing Th1 and Th17-mediated neuroinflammation, highlighting its role in immune regulation and potential neuroprotective function[4][5]. Compared with related isoforms like IL-4, IL-13 demonstrates distinct receptor-binding affinities and downstream signaling kinetics, which influence the magnitude and specificity of cellular responses[6]. Pharmacological agonists of IL-13 or IL-13R pathways have been employed experimentally to modulate immune cell polarization and cytokine production, whereas IL-13 neutralizing antibodies are utilized to dissect isoform-specific effects in inflammatory models[1][6]. These experimental applications provide insight into IL-13’s selective regulation of immune pathways, offering mechanistic understanding and design considerations for cytokine-targeted interventions in autoimmune and allergic diseases[2].
References:
- [1]. Mannie MD, et al. Cytokine-neuroantigen fusion proteins as a new class of tolerogenic, therapeutic vaccines for treatment of inflammatory demyelinating disease in rodent models of multiple sclerosis. Front Immunol. 2012 Aug 20;3:255. [Content Brief]
- [2]. Liu Y, et al. Therapeutic efficacy of suppressing the Jak/STAT pathway in multiple models of experimental autoimmune encephalomyelitis. J Immunol. 2014 Jan 1;192(1):59-72. [Content Brief]
- [3]. Benveniste EN, et al. Involvement of the janus kinase/signal transducer and activator of transcription signaling pathway in multiple sclerosis and the animal model of experimental autoimmune encephalomyelitis. J Interferon Cytokine Res. 2014 Aug;34(8):577-88. [Content Brief]
- [4]. Peón AN, et al. Helminth Products Potently Modulate Experimental Autoimmune Encephalomyelitis by Downregulating Neuroinflammation and Promoting a Suppressive Microenvironment. Mediators Inflamm. 2017;2017:8494572. [Content Brief]
- [5]. Johnson BM, et al. STING Agonist Mitigates Experimental Autoimmune Encephalomyelitis by Stimulating Type I IFN-Dependent and -Independent Immune-Regulatory Pathways. J Immunol. 2021 May 1;206(9):2015-2028. [Content Brief]
- [6]. Vandenbroeck K, et al. Inhibiting cytokines of the interleukin-12 family: recent advances and novel challenges. J Pharm Pharmacol. 2004 Feb;56(2):145-60. [Content Brief]
-
IL-13 Related Products (55)
Related Products (55)
-
Recombinant Proteins (19)
-
House Dust Mite Extract, from D.pteronyssinus
0 ImagesCat. No.: HY-NP159AHouse Dust Mite Extract, from D. pteronyssinus is a house dust mite allergenic extract derived from Dermatophagoides pteronyssinus. House Dust Mite Extract, from D. pteronyssinus increases serum IgE, IgG1 and IgG2a levels, and elevates the levels of Interleukins 4, 5, 6, 10, 13 and 17. House Dust Mite Extract, from D. pteronyssinus induces significant asthmatic pathological changes. House Dust Mite Extract, from D. pteronyssinus can be used in studies related to asthma and allergic conjunctivitis.
-
Suplatast (Tosilate)
0 ImagesSynonyms: IPD 1151T
-
TSLP-IN-1
0 ImagesTSLP-IN-1 is a potent thymic stromal lymphopoietin (TSLP) inhibitor. TSLP-IN-1 disrupts TSLP-TSLPR protein-protein interaction, and downregulates IL-4 and IL-13. TSLP-IN-1 can be used for the research of inflammation diseases, such as skin disease, asthma, and allergies.
-
Desoximetasone
0 ImagesDesoximetasone is a corticosteroid and a substrate of cytochrome P450 3A4. Desoximetasone has anti-inflammatory, anti-allergic, and immunosuppressive effects. Desoximetasone can be used in the research of various skin diseases, such as skin allergies, atopic dermatitis, and psoriasis.
-
(±)-Praeruptorin A
0 Images(±)-Praeruptorin A, a coumarin compound, is the main bioactive component in Peucedani Radix. As a calcium channel blocker, (±)-Praeruptorin A exhibits great antihypertensive effects. In addition, (±)-Praeruptorin A also has the effects of relaxing vascular smooth muscle, inhibiting airway inflammation and airway hyperresponsiveness. (±)-Praeruptorin A can be used for the research of allergic asthma, hypertension and other diseases.
-
BP79
0 ImagesCat. No.: HY-206870CAS No.: 3104965-33-2BP79 is a potent TSLP receptor inhibitor. BP79 disrupts TSLP-mediated ternary complex formation, blocks TSLPR-IL7Rα co-localization, binds and stabilizes TSLPR, and inhibits phosphorylated STAT3/6. BP79 suppresses immune cell infiltration, secretion of IL-13, IL-4. BP79 can be used for the research of inflammation diseases, such as atopic dermatitis, allergic asthma, and allergic rhinitis.
-
SM-17
0 ImagesCat. No.: HY-P991266SM-17 is a human monoclonal antibody targeting IL-17RB. SM-17 binds to human IL-17RB, inhibits the dimerization of IL-17RA/IL-17RB, blocks IL-25-induced phosphorylation of ERK1/2 and STAT5, and suppresses Th2-mediated inflammatory responses. SM-17 inhibits the secretion of IL-5, IL-9, IL-13 and IL-4, impairs the proliferation/expansion of ILC2 and Th2 cells, and restores filaggrin expression. SM-17 reduces immune cell infiltration, epidermal hyperplasia, goblet cell hyperplasia, collagen deposition, ear swelling and scratching behavior in animal models. SM-17 can be used in research related to atopic dermatitis and allergic asthma.
-
Donzakimig
0 ImagesSynonyms: UCB-1381Donzakimig is a trispecific anti-IL-13/IL-22/HSA antibody. Donzakimig adopts a Fab-scFv-scFv structural format (without an Fc region), in which the Fab domain is linked to the scFv domains via a S (G4S)2 linker. Donzakimig binds to and inhibits the activities of IL-13 and IL-22, thereby blocking the signal transduction of these two cytokines. Donzakimig can extend its serum half-life by binding to human serum albumin, enhancing its in vivo stability and achieving long-acting efficacy. Donzakimig can be used in research on moderate-to-severe atopic dermatitis, moderate-to-severe asthma (especially eosinophilic type), psoriasis, inflammatory bowel disease, and other conditions.
-
DOTA-Pep-1L TFA
0 ImagesCat. No.: HY-P11287APurity: 98.60%DOTA-Pep-1L TFA is a polypeptide formed by the conjugation of DOTA and Pep-1L. DOTA-Pep-1L TFA specifically binds to IL13RA2 and can be used for the synthesis of targeted polypeptides. DOTA-Pep-1L TFA yields the isotopically labeled product [225Ac]DOTA-Pep-1L, which exerts α-radiation killing effects on orthotopic glioma cells and extends the median survival time of mice bearing orthotopic glioma models after stereotactic injection. DOTA-Pep-1L TFA can be used for PET imaging, tumor targeting and glioma research.
-
Zumilokibart
0 ImagesCat. No.: HY-P991729CAS No.: 3037408-64-0Synonyms: APG-777Zumilokibart (APG-777) is an anti-IL-13 IgG1κ type humanized antibody. The recommed isotype control is Human IgG1 kappa, Isotype Control (HY-P99001). Zumilokibart can be used for the research of atopic dermatitis (AD).
-
Romilkimab
0 ImagesSynonyms: SAR156597
-
TSLP modulator-1
0 ImagesCat. No.: HY-181006Purity: 99.61%TSLP modulator-1 (Compound 14O) is a potent TSLP signaling modulator. TSLP modulator-1 exhibits potent inhibition of CCL17 and IL-1β mRNA expression. TSLP modulator-1 attenuates the protein levels of IL-6, IL-4 and IL-13. TSLP modulator-1 significantly attenuates calcium influx. TSLP modulator-1 exerts anti-inflammatory effects. TSLP modulator-1 effectively alleviates pruritus and atopic dermatitis-like symptoms.
-
Dectrekumab
0 ImagesCat. No.: HY-P99846CAS No.: 1528523-94-5Synonyms: QAX576Dectrekumab (QAX576) is a human monoclonal antibody that targets IL-13. Dectrekumab significantly improves intraepithelial esophageal eosinophil counts and dysregulated esophageal disease-related transcripts with Eosinophilic esophagitis (EoE) in a sustained manner and can be used for inflammation and immunology related research.
-
Abrezekimab
0 ImagesCat. No.: HY-P99417CAS No.: 2043952-59-4Synonyms: UCB4144; VR 942
-
IL13Rα2 D1
0 ImagesIL13Rα2 D1 is an effective IL-13/IL13Rα2 signaling axis inhibitor. IL13Rα2 D1 can inhibit IL-13-induced cell adhesion, migration, invasion, and proliferation. IL13Rα2 D1 can inhibit FAK, Src, AKT, ERK1/2 phosphorylation, and MMP expression. IL13Rα2 D1 can be used for research on cancers such as colorectal cancer.
-
Ompekimig
0 ImagesCat. No.: HY-P991150CAS No.: 2981477-39-6Ompekimig is an immunoglobulin monoclonal antibody that targets IL-4, IL-13, IL-33. Ompekimig shows potential for use in immune-mediated inflammatory diseases such as asthma and atopic dermatitis.
-
CNTO-5825
0 ImagesCat. No.: HY-P991258Purity: 98.18%CNTO-5825 is a humanized monoclonal antibody inhibitor targeting interleukin-13 (IL-13). CNTO-5825 is promising for research of Th2-type inflammatory related diseases such as asthma and atopic dermatitis.
-
Solaprubart
0 ImagesSynonyms: STAR-0310Solaprubart (STAR-0310) is a fully human IgG1 subtype monoclonal antibody targeting OX40 (CD134/TNFRSF4), with a Kd of 7.2 nM. By blocking the OX40/OX40L co-stimulatory signal, Solaprubart effectively inhibits cytokine release (IFN-γ, TNF-α, IL-5, IL-13) from activated effector T cells (Th1/Th2/Th17-associated). Solaprubart can be used in research related to moderate-to-severe atopic dermatitis.
-
GED 0507-34-Levo
0 ImagesCat. No.: HY-W109107CAS No.: 921195-93-9
